FR2381525A1 - Compositions pharmaceutiques antioestrogenes - Google Patents

Compositions pharmaceutiques antioestrogenes

Info

Publication number
FR2381525A1
FR2381525A1 FR7805566A FR7805566A FR2381525A1 FR 2381525 A1 FR2381525 A1 FR 2381525A1 FR 7805566 A FR7805566 A FR 7805566A FR 7805566 A FR7805566 A FR 7805566A FR 2381525 A1 FR2381525 A1 FR 2381525A1
Authority
FR
France
Prior art keywords
compound
tamoxifen
estrogen
exhibits
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7805566A
Other languages
English (en)
Other versions
FR2381525B1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imperial Chemical Industries Ltd
Original Assignee
Imperial Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial Chemical Industries Ltd filed Critical Imperial Chemical Industries Ltd
Publication of FR2381525A1 publication Critical patent/FR2381525A1/fr
Application granted granted Critical
Publication of FR2381525B1 publication Critical patent/FR2381525B1/fr
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne l'industrie pharmaceutique. Elle a pour objet le 1(p- beta -di-méthylaminoéthoxyphényl)-trans-1-(p-hydroxyphényl)-2-phénylbut-1-ène, appelé ci-après composé I, qui manifeste une activité anti-oestrogène du même ordre que celle du tamoxifen, mais ne présente que l'activité oestrogene faible atypique du tamoxifen au lieu de l'activité oestrogène à laquelle on peut s'attendre d'un composé hydroxylé de ce genre, et un procédé pour induire un e fet anti-oestrogène chez les animaux homéothermes, y compris l'homme, suivant lequel on administre par voie orale ou parentérale une quantité efficace du composé I ou d'un de ses sels pharmaceutiquement acceptables. Le composé I est préféré pour le traitement de la stérilité anovulatoire et des tumeurs du sein.
FR7805566A 1977-02-28 1978-02-27 Compositions pharmaceutiques antioestrogenes Granted FR2381525A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8273/77A GB1560274A (en) 1977-02-28 1977-02-28 Phenylbut 1-ene derivatives having antiostrogenicactivity

Publications (2)

Publication Number Publication Date
FR2381525A1 true FR2381525A1 (fr) 1978-09-22
FR2381525B1 FR2381525B1 (fr) 1980-08-29

Family

ID=9849341

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7805566A Granted FR2381525A1 (fr) 1977-02-28 1978-02-27 Compositions pharmaceutiques antioestrogenes

Country Status (9)

Country Link
US (1) US4198435A (fr)
JP (1) JPS53107425A (fr)
AU (1) AU515458B2 (fr)
BE (1) BE864359A (fr)
DE (1) DE2807599A1 (fr)
FR (1) FR2381525A1 (fr)
GB (1) GB1560274A (fr)
NL (1) NL7801739A (fr)
NZ (1) NZ186403A (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2401132A1 (fr) * 1977-08-22 1979-03-23 Ici Ltd Nouveaux derives de triphenylbutene-1, leur procede de production et composition pharmaceutique les contenant

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE637389A (fr) * 1962-09-13
ATE2423T1 (de) * 1978-11-07 1983-03-15 Imperial Chemical Industries Plc 1-acyloxyphenyl-1,2-diphenylalken-derivate, verfahren zu deren herstellung und eine diese derivate enthaltende pharmazeutische zusammensetzung.
DE3046719C2 (de) * 1980-12-11 1983-02-17 Klinge Pharma GmbH, 8000 München 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
CA1289570C (fr) * 1986-06-16 1991-09-24 Tetsuji Asao Derives 1,1,2-triaryl-1-alcenes
ES2044860T3 (es) * 1987-04-21 1994-01-16 Heumann Pharma Gmbh & Co Estables aductos con disolventes de z-1-(p-beta-di-metil-amino-etoxi-fenil)-1-(p-hidroxi-fenil)-2-fenil-but-1-eno.
US5204337A (en) * 1988-10-31 1993-04-20 Endorecherche Inc. Estrogen nucleus derivatives for use in inhibition of sex steroid activity
ZA924811B (en) * 1991-06-28 1993-12-29 Endorecherche Inc Controlled release systems and low dose androgens
DE4320896A1 (de) * 1993-06-24 1995-01-05 Denecke Rainer Dr Med Vet Präparat zur Therapie und Prophylaxe von Demenz-Erkrankungen
DE4407742C1 (de) * 1994-03-08 1995-06-22 Hexal Pharma Gmbh Transdermales System in Form eines Pflasters mit einem Tamoxifen-Derivat
US5681835A (en) * 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
AU696788B2 (en) * 1994-06-27 1998-09-17 Neutron Therapies Inc. Boron-containing hormone analogs and methods of their use in imaging or killing cells having hormone receptors
NZ502738A (en) 1997-08-15 2002-06-28 Univ Duke Triphenylethylene derivatives similar to tamoxifen or toremifene derivatives
US6245352B1 (en) * 1999-04-27 2001-06-12 Eli Lilly And Company Pharmaceutical formulation
HUP0200871A3 (en) 1999-05-04 2004-04-28 Strakan Int Ltd Androgen glycosides and androgenic activity thereof
US20030032676A1 (en) * 2001-08-09 2003-02-13 Kimelberg Harold K. Drugs for treatment of cerebral injury and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1568834A1 (de) * 1962-09-13 1970-11-26 Ici Ltd Verfahren zur Herstellung von cis- und trans-Isomeren von Alkenderivaten

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1568834A1 (de) * 1962-09-13 1970-11-26 Ici Ltd Verfahren zur Herstellung von cis- und trans-Isomeren von Alkenderivaten

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2401132A1 (fr) * 1977-08-22 1979-03-23 Ici Ltd Nouveaux derives de triphenylbutene-1, leur procede de production et composition pharmaceutique les contenant

Also Published As

Publication number Publication date
FR2381525B1 (fr) 1980-08-29
NZ186403A (en) 1984-08-24
DE2807599C2 (fr) 1987-04-09
AU3319078A (en) 1979-08-16
JPS6339567B2 (fr) 1988-08-05
US4198435A (en) 1980-04-15
AU515458B2 (en) 1981-04-02
NL7801739A (nl) 1978-08-30
JPS53107425A (en) 1978-09-19
DE2807599A1 (de) 1978-08-31
GB1560274A (en) 1980-02-06
BE864359A (fr) 1978-08-28

Similar Documents

Publication Publication Date Title
FR2381525A1 (fr) Compositions pharmaceutiques antioestrogenes
Thompson et al. Sulfone metabolite of sulindac inhibits mammary carcinogenesis
FR2448348A1 (fr) Composition pharmaceutique comprenant une acyl-carnitine pour le traitement du metabolisme cerebral perturbe
TNSN96104A1 (fr) Trihydrate de metahensulfonate de (1s,2s)-1-(4-hydroxyphenyl) -2-(4-hydroxy-4-phenylpiperidine-1-yl)-1-propanol et composition pharmaceutique le contenant
ATE221776T1 (de) Zusammensetzungen, die einen die mastzellendgranulation blockierenden h-1 rezeptorantagonisten als wirkstoff enthalten, für die behandlung von endogenen, schmerzhaften gastrointestinalen beschwerden nichtentzündlichen,nichtulzerativen ursprungs
FR2445146A1 (fr) Medicament a prise orale contenant une substance inhibitrice de l'inflammation et un ou plusieurs phospholipides
FR2404625A1 (fr) Nouveaux 4-aminocyclohexanols et composition pharmaceutique les contenant
CA2330500A1 (fr) Compositions pharmaceutiques gelifiables
TNSN98150A1 (fr) Derives d'acides aryloxyarylsulfonylaminohydroxamiques ; procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN97087A1 (fr) 4(3h)-quinazolinones 2,3-disubstituees nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2430228A1 (fr) Medicament contre les maladies de la peau
TNSN99203A1 (fr) Compositions pharmaceutiques pour le traitement de la migraine, et procede pour leur preparation
TNSN99132A1 (fr) Une composition pour la prevention et/ou le traitement de l'osteoporose ou des alterations dues au syndrome de menopause
DE69534564D1 (de) Verwendung von 2-hydroxy-5-phenylazobenzoesäure-derivaten als wirkstoffe zur chemoprävention und chemotherapie von kolonkrebs
CA2231342A1 (fr) Composition pharmaceutique pour administration par voie orale
EP0065513A1 (fr) Compositions pharmaceutiques antimycotiques synergiques et leur procede de preparation.
BE899564A (fr) Composition pharmaceutique pour l'administration parenterale a base de nimodipin et procede pour sa preparation.
KR950031060A (ko) 골다공증 치료용 약제학적 조성물
Alsarraf et al. Acetylation: a lysine modification with neuroprotective effects in ischemic retinal degeneration
FR2554346B1 (fr) Ensemble et procede pour l'administration de gangliosides et de leurs derives par inhalation et compositions pharmaceutiques les contenant
BG98827A (en) Pharmaceutical composition and method for its preparation
FR2387033A1 (fr) Composition therapeutique contenant une ou plusieurs substances actives chimiquement modifiees
FR2420974A1 (fr) Medicament a base de derives de l'uracile
TNSN98049A1 (fr) Composition pharmaceutique a residence gastrique.
Ford-Hutchinson 5-Lipoxygenase activation in psoriasis: a dead issue?